ClinVar Miner

Submissions for variant NM_000151.4(G6PC1):c.113A>T (p.Asp38Val) (rs104894565)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000507730 SCV000603763 pathogenic not specified 2016-09-30 criteria provided, single submitter clinical testing
Invitae RCV000012784 SCV000776251 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2020-09-20 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid with valine at codon 38 of the G6PC protein (p.Asp38Val). The aspartic acid residue is highly conserved and there is a large physicochemical difference between aspartic acid and valine. This variant is present in population databases (rs104894565, ExAC 0.001%). This variant has been reported as homozygous or compound heterozygous with a rare variant in several individuals affected with glycogen storage disease type Ia (PMID: 8733042, 9359038, 10834516, 11310582, 10070617). Experimental studies have shown that this missense change results in significantly decreased activity of the G6PC protein (PMID: 11739393, 9359038). For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000012784 SCV000917379 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2018-02-01 criteria provided, single submitter clinical testing Variant summary: G6PC c.113A>T (p.Asp38Val) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8.1e-06 in 246454 control chromosomes in gnomAD and literature. This frequency is not significantly higher than expected for a pathogenic variant in G6PC causing Glycogen Storage Disease Type Ia (8.1e-06 vs 1.70E-03), allowing no conclusion about variant significance. c.113A>T has been reported in the literature in multiple individuals affected with Glycogen Storage Disease Type Ia, including one confirmed homozygote (Chevalier-Porst_1996, Stroppiano_1999, Reis_2001). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in abolished enzymatic activity (Chevalier-Porst_1996). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Baylor Genetics RCV000012784 SCV001163777 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA criteria provided, single submitter clinical testing
OMIM RCV000012784 SCV000033024 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 1996-05-01 no assertion criteria provided literature only
Counsyl RCV000012784 SCV001132392 likely pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2018-06-25 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.